The investigations target potential breaches of fiduciary duty by boards of directors during the sale or merger processes of these companies. For Arcosa, Inc. (NYSE: ACA), the inquiry follows a proposed sale to CRH Americas, Inc. at $150.00 per share. Similarly, the firm is reviewing the merger between Bio Green Med Solution, Inc. (NASDAQ: BGMS) and Future NRG Sdn. Bhd., alongside the combination of Non-Invasive Monitoring Systems, Inc. (OTCPK: NIMU) and Gravitics, Inc., where shareholders stand to retain a 4.5% stake in the combined entity.

First Seacoast Bancorp, Inc. (NASDAQ: FSEA) faces the most immediate pressure, with a shareholder vote scheduled for August 27, 2026. The proposed sale to Cambridge Financial Group, Inc. offers investors $17.25 per share in cash. Shareholders concerned about the valuation or the integrity of these deals may contact the firm for a review of their rights, as the firm emphasizes its history of litigating securities class actions from its headquarters in the Empire State Building.